查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1618841

粒子治疗市场：按治疗类型、成分、成分、癌症类型、最终用户 - 2025-2030 年全球预测

Particle Therapy Market by Therapy Type (Heavy Ion Therapy, Proton Therapy), Component (Product, Service), Configuration, Cancer Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年粒子治疗市值为7.7241亿美元，预计到2024年将达到8.315亿美元，复合年增长率为7.94%，到2030年将达到13.1887亿美元。

粒子疗法主要包括质子疗法和重离子疗法，是一种利用带电粒子进行癌症治疗的外束放射疗法。它能够精确地瞄准肿瘤，同时最大限度地减少对周围健康组织的损害，从而减少了与传统放射治疗相关的副作用，满足了癌症治疗的关键需求。它已应用于多种癌症，包括儿童癌症、前列腺癌和头颈癌，并且在眼部肿瘤和神经系统疾病的治疗中变得越来越效用。主要的最终用途部分是医疗设施，例如专科医院和癌症治疗中心。

主要市场统计
基准年[2023] 77241万美元
预计年份 [2024] 8.315 亿美元
预测年份 [2030] 1,318.87 百万美元
复合年增长率（%） 7.94%

市场成长的推动因素包括治疗系统的技术进步、癌症发生率的增加、对先进治疗方案认识的提高以及政府的支持措施。笔射束扫描和调变质子治疗的最新创新提高了治疗精度，并为投资研发的公司创造了有利可图的机会。然而，高安装和营运成本、有限的设施可用性以及复杂的监管核准等挑战正在阻碍市场扩张。此外，缺乏熟练的专业人员是开发中地区的一个主要障碍。

鼓励希望利用成长机会的公司投资具有成本效益的技术，并与医疗保健提供者建立合作伙伴关係以建立新的治疗中心。此外，扩大培训计划并扩展到尚未开发的新兴市场可以促进更广泛地获得和采用粒子疗法。

由于专注于改善临床结果和减轻患者和医疗保健提供者的经济负担的技术创新，粒子治疗市场仍然具有竞争力。专注于开发混合治疗解决方案以及将人工智慧融入个人化治疗计划的公司将保持在该行业的前沿。儘管存在经济和物流方面的限制，但在持续的研发努力以及支持先进癌症治疗的不断发展的监管环境的支持下，市场轨迹仍然充满希望。这些进步有望重塑治疗模式并扩大粒子治疗在全球的应用潜力。

市场动态：揭示快速发展的粒子治疗市场的关键市场洞察

供需的动态交互作用正在改变粒子治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 癌症治疗需要先进的治疗方法
    • 在临床测试中越来越多地采用粒子束疗法
    • 世界各地粒子治疗中心的增加
  • 市场限制因素
    • 粒子束治疗设备和程序高成本，粒子束治疗的保险范围有限
  • 市场机会
    • 正在进行的质子治疗研究计划
    • 带电粒子束治疗的技术进步和个人化癌症治疗策略的实现
  • 市场问题
    • 与粒子束治疗辐射暴露相关的风险

波特五力：引领粒子治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解粒子治疗市场的外部影响

外部宏观环境因素在塑造粒子治疗市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解粒子束治疗市场的竞争格局

对粒子治疗市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：粒子治疗市场供应商绩效评估

FPNV定位矩阵是评估粒子治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製粒子治疗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，粒子束治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开发：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症治疗需要先进的治疗方法
      • 在临床测试中更多地采用粒子束疗法
      • 世界各地的粒子治疗中心不断增加
    • 抑制因素
      • 粒子治疗设备和程序的成本很高，而且粒子治疗的保险范围有限。
    • 机会
      • 正在进行的质子治疗调查计画
      • 带电粒子束治疗的技术进步和个人化癌症治疗策略的实现
    • 任务
      • 与粒子束治疗辐射暴露相关的风险
  • 市场区隔分析
    • 治疗类型：消费者更喜欢质子治疗，因为对周围组织损伤的风险较低
    • 组件：高精度增加了产品组件的使用，以治疗重要器官附近的固态肿瘤
    • 配置：可以同时治疗多个患者的多房间系统的可能性
    • 癌症类型：由于降低了健康组织的风险，粒子疗法在头颈癌的应用不断扩大
    • 最终使用者：粒子治疗在医院和医疗机构致力于提供高品质护理方面发挥重要作用
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章粒子治疗市场：依治疗类型

  • 介绍
  • 重粒子线治疗
  • 质子治疗

第七章粒子治疗市场：依组成部分

  • 介绍
  • 产品
    • 迴旋加速器
    • 同步迴旋加速器
    • 同步加速器
  • 服务

第八章粒子治疗市场：依成分分类

  • 介绍
  • 多房间系统
  • 单间系统

第九章粒子束治疗市场：依癌症类型

  • 介绍
  • 乳癌
  • 头颈癌
  • 肺癌
  • 儿童癌症
  • 摄护腺癌

第 10 章 粒子治疗市场：依最终使用者分类

  • 介绍
  • 门诊手术中心
  • 医院/诊所

第十一章 美洲粒子治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太粒子治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的粒子治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • IBA 与 PARTICLE 启动 FLASH 质子治疗研究伙伴关係
    • P-Cure 获得 FDA核准用于坐位治疗的质子治疗系统，并开始在以色列治疗患者
    • Terapet 筹集了 230 万瑞士法郎用于下一代癌症治疗技术
  • 战略分析和建议

公司名单

  • Advanced Oncotherapy plc
  • B dot Medical Inc.
  • Best Particle Therapy, Inc.
  • BioSig Technologies Inc.
  • Covenant Health
  • Danfysik A/S
  • Elekta AB
  • Hitachi, Ltd.
  • IBA International
  • Koninklijke Philips NV
  • Mevion Medical Systems
  • Mitsubishi Electric Corporation
  • New Mexico Cancer Center
  • Optivus Proton Therapy, Inc.
  • P-Cure Ltd
  • ProTom International
  • Provision Healthcare, LLC
  • PTW Freiburg GmbH
  • SAH Global LLC
  • Shanghai APACTRON Particle Equipment Co., Ltd.
  • Siemens Healthineers GmbH
  • Stantec Inc.
  • Sumitomo Heavy Industries, Ltd.
  • Toshiba Medical Systems Corporation
  • Xstrahl Ltd.
Product Code: MRR-335201F2E2B6

The Particle Therapy Market was valued at USD 772.41 million in 2023, expected to reach USD 831.50 million in 2024, and is projected to grow at a CAGR of 7.94%, to USD 1,318.87 million by 2030.

Particle therapy, primarily comprising proton and heavy ion therapy, is a form of external beam radiotherapy utilizing charged particles for cancer treatment. Due to its precision in targeting tumors while minimizing damage to surrounding healthy tissues, it addresses a critical necessity in cancer treatment, reducing side effects associated with conventional radiation therapy. Applications span a variety of cancers, including pediatric, prostate, and head and neck cancers, with growing utility in treating ocular tumors and neurological disorders. End-use sectors primarily include healthcare facilities like specialized hospitals and cancer treatment centers.

KEY MARKET STATISTICS
Base Year [2023] USD 772.41 million
Estimated Year [2024] USD 831.50 million
Forecast Year [2030] USD 1,318.87 million
CAGR (%) 7.94%

Market growth is driven by technological advancements in treatment delivery systems, increasing incidence of cancer, rising awareness about advanced treatment options, and supportive government initiatives. Recent innovations in pencil beam scanning and intensity-modulated proton therapy have heightened treatment accuracy, presenting lucrative opportunities for companies investing in R&D. However, challenges such as high installation and operational costs, limited availability of facilities, and intricate regulatory approvals constrain market expansion. Additionally, the lack of skilled professionals poses a significant barrier in developing regions.

For businesses aiming to capitalize on growth opportunities, investing in cost-effective technologies and building collaborations with healthcare providers to establish new treatment centers are recommended. Furthermore, enhancing training programs and expanding into untapped emerging markets could foster broader accessibility and adoption of particle therapy.

The particle therapy market remains competitive, with innovation centered on improving clinical outcomes and reducing financial burdens for patients and providers. Companies focusing on developing hybrid therapy solutions and integrating AI for personalized treatment planning can stay at the forefront of the industry. Despite financial and logistical constraints, the market's trajectory remains promising, bolstered by continuous R&D efforts and evolving regulatory landscapes favoring advanced cancer therapies. Such advancements promise to reshape treatment paradigms and expand the potential for particle therapy applications worldwide.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Particle Therapy Market

The Particle Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Need for advanced therapies in cancer treatment
    • Rise in adoption of particle therapy in clinical trials
    • Growing number of particle therapy centers worldwide
  • Market Restraints
    • High cost of particle therapy equipment and procedures, along with limited insurance coverage for particle therapy
  • Market Opportunities
    • Ongoing proton therapy research programs
    • Technological advances in charged-particle therapy and enabling personalized cancer treatment strategies
  • Market Challenges
    • Risk associated with the particle therapy radiation exposure

Porter's Five Forces: A Strategic Tool for Navigating the Particle Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Particle Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Particle Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Particle Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Particle Therapy Market

A detailed market share analysis in the Particle Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Particle Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Particle Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Particle Therapy Market

A strategic analysis of the Particle Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Particle Therapy Market, highlighting leading vendors and their innovative profiles. These include Advanced Oncotherapy plc, B dot Medical Inc., Best Particle Therapy, Inc., BioSig Technologies Inc., Covenant Health, Danfysik A/S, Elekta AB, Hitachi, Ltd., IBA International, Koninklijke Philips N.V., Mevion Medical Systems, Mitsubishi Electric Corporation, New Mexico Cancer Center, Optivus Proton Therapy, Inc., P-Cure Ltd, ProTom International, Provision Healthcare, LLC, PTW Freiburg GmbH, SAH Global LLC, Shanghai APACTRON Particle Equipment Co., Ltd., Siemens Healthineers GmbH, Stantec Inc., Sumitomo Heavy Industries, Ltd., Toshiba Medical Systems Corporation, and Xstrahl Ltd..

Market Segmentation & Coverage

This research report categorizes the Particle Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy Type, market is studied across Heavy Ion Therapy and Proton Therapy.
  • Based on Component, market is studied across Product and Service. The Product is further studied across Cyclotrons, Synchrocyclotrons, and Synchrotrons.
  • Based on Configuration, market is studied across Multi-room System and Single-room System.
  • Based on Cancer Type, market is studied across Breast Cancer, Head & Neck Cancer, Lung Cancer, Pediatric Cancer, and Prostate Cancer.
  • Based on End-User, market is studied across Ambulatory Surgery Centers and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Need for advanced therapies in cancer treatment
      • 5.1.1.2. Rise in adoption of particle therapy in clinical trials
      • 5.1.1.3. Growing number of particle therapy centers worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of particle therapy equipment and procedures, along with limited insurance coverage for particle therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing proton therapy research programs
      • 5.1.3.2. Technological advances in charged-particle therapy and enabling personalized cancer treatment strategies
    • 5.1.4. Challenges
      • 5.1.4.1. Risk associated with the particle therapy radiation exposure
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapy Type: Consumer preference for proton therapy as it provides a reduced risk of damage to surrounding tissues
    • 5.2.2. Component: Rising utilization of product components for treating solid tumors near vital organs due to their high accuracy
    • 5.2.3. Configuration: Potential of a multi-room system for treating a larger number of patients concurrently
    • 5.2.4. Cancer Type: Expanding usage of particle therapy for head & neck cancer owing to reduced risk on healthy tissue
    • 5.2.5. End-User: Significant role of particle therapy in hospitals & clinicals as they strive to provide high-quality care
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Particle Therapy Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Heavy Ion Therapy
  • 6.3. Proton Therapy

7. Particle Therapy Market, by Component

  • 7.1. Introduction
  • 7.2. Product
    • 7.2.1. Cyclotrons
    • 7.2.2. Synchrocyclotrons
    • 7.2.3. Synchrotrons
  • 7.3. Service

8. Particle Therapy Market, by Configuration

  • 8.1. Introduction
  • 8.2. Multi-room System
  • 8.3. Single-room System

9. Particle Therapy Market, by Cancer Type

  • 9.1. Introduction
  • 9.2. Breast Cancer
  • 9.3. Head & Neck Cancer
  • 9.4. Lung Cancer
  • 9.5. Pediatric Cancer
  • 9.6. Prostate Cancer

10. Particle Therapy Market, by End-User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgery Centers
  • 10.3. Hospitals & Clinics

11. Americas Particle Therapy Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Particle Therapy Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Particle Therapy Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. IBA and PARTICLE Initiate FLASH Proton Therapy Research Partnership
    • 14.3.2. P-Cure Receives FDA Approval For Proton Therapy System For Treatment in Seated Position and Will Begin Treating Patients In Israel
    • 14.3.3. Terapet raises CHF 2.3 million for its next-generation cancer treatment technology
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Advanced Oncotherapy plc
  • 2. B dot Medical Inc.
  • 3. Best Particle Therapy, Inc.
  • 4. BioSig Technologies Inc.
  • 5. Covenant Health
  • 6. Danfysik A/S
  • 7. Elekta AB
  • 8. Hitachi, Ltd.
  • 9. IBA International
  • 10. Koninklijke Philips N.V.
  • 11. Mevion Medical Systems
  • 12. Mitsubishi Electric Corporation
  • 13. New Mexico Cancer Center
  • 14. Optivus Proton Therapy, Inc.
  • 15. P-Cure Ltd
  • 16. ProTom International
  • 17. Provision Healthcare, LLC
  • 18. PTW Freiburg GmbH
  • 19. SAH Global LLC
  • 20. Shanghai APACTRON Particle Equipment Co., Ltd.
  • 21. Siemens Healthineers GmbH
  • 22. Stantec Inc.
  • 23. Sumitomo Heavy Industries, Ltd.
  • 24. Toshiba Medical Systems Corporation
  • 25. Xstrahl Ltd.

LIST OF FIGURES

  • FIGURE 1. PARTICLE THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. PARTICLE THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PARTICLE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PARTICLE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. PARTICLE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. PARTICLE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PARTICLE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PARTICLE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PARTICLE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PARTICLE THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PARTICLE THERAPY MARKET SIZE, BY HEAVY ION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PROTON THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CYCLOTRONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SYNCHROCYCLOTRONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SYNCHROTRONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SERVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PARTICLE THERAPY MARKET SIZE, BY MULTI-ROOM SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SINGLE-ROOM SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PARTICLE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PARTICLE THERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PARTICLE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PEDIATRIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PARTICLE THERAPY MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PARTICLE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. PARTICLE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 280. PARTICLE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023